The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.
All News
Article
Article
Patients with gout not only have a well-recognized increased risk of dying from cardiovascular (CV) disease, but also have higher all-cause mortality and die prematurely from other diseases, a Swedish study indicated.
Article
Rheumatology Leaders Join a Coalition of National Medical Specialties in Urging Congress to Protect Patients from Prior Authorization Requirements in Medicare Advantage Plans
Article
Dr. Jack Cush reviews the news and journal articles of note from this past week on RheumNow.com.
Article
Reuters has reported that Mallinckrodt Plc has tentatively agreed to pay $15.4 million to resolve a US Justice Department investigation into company promotional practices for Acthar gel.
UK study shows SLE admissions increased from 8.97 to 9.04 per 100,000 ( p < 0.001) between 1998 & 2015. By comparison, RA admissions rose from 71.0 to 171.6 per 100,000 ( p < 0.001). YET total bed days for SLE & RA fell by 60% and 90%, respectively https://t.co/5IeZh8o8M5
EULAR is a truly pan-European organisation fostering a multitude of activities in areas of research, patient care, and education. Learn more at #EULAR2019! #rheumatology #rheumarthritis #lupus https://t.co/sGSuKnXpNg
NHANES study shows Psoriatic arthritis found that #PsA patients report more hearing difficulties (OR 1.50, p 0.043), visit mental health provider (OR 1.62, p = 0.084), 1.62 more days of poor mental health (p = 0.033), and depression (OR 2.01, p = 0.015) https://t.co/xdh4MfWxbA
https://t.co/V10S4oVFsv would love to feature your tweets in our coverage of #EULAR2019 from Madrid. Be sure to include these 3 in your tweet- @RheumNow #EULAR2019 & the abstract # https://t.co/WqqX4w4dmd
GSK announced that the FDA has approved the IL-5 inhibitor Nucala (mepolizumab), as an autoinjector and a pre-filled safety syringe, (for use in severe eosinophilic asthma & disease eosinophilic granulomatosis with polyangiitis (EGPA) https://t.co/XXGJxLDta7
Hear nine experts talk about biosimilars in “Therapeutic Update: Biosimilars in Rheumatology”, a video series brought to viewers by Sandoz. Now available on RheumNow. https://t.co/1vmnEJqOSi #sponsored #biosimilars
US Dermatologists serving on FDA advisory panels during derm drug approval: study shows half received at least 1payment from pharma; 27% > $1000, 15% >$50K, 9% > $100K. Payments from competitors outnumbered manufacturers https://t.co/bNmjkQFOJM
The cost of healthcare in inflammatory bowel disease is >3 times a healthy population. Overall, average annual costs for patients with IBD were $22,987 compared with $6,956 without IBD, the study found. Out-of-pocket costs were more than doubled . https://t.co/FopLzw4ypU
https://t.co/V10S4oVFsv would love to feature your tweets in our coverage of #EULAR2019 from Madrid. Be sure to include these 3 in your tweet- @RheumNow #EULAR2019 & the abstract # https://t.co/WqqX4w4dmd
RheumNow Podcast is up! Info on Drug Ad Transparency, FDA CBD oil hearing, OI, TB testing, Stem Cell Clinics and more. Watch it here >>https://t.co/MbE91908Er or listen to the podcast on iTunes or SoundCloud >> https://t.co/FbEn1vWriU
Clinical Trials Benchmark for Biosimilar Development is one of several educational videos available in the "Therapeutic Update: Biosimilars in Rheumatology" video series, sponsored by Sandoz, Inc. and now available on RheumNow. https://t.co/1vmnEJqOSi #sponsored #biosimilars
QD Clinic - daily lessons and cases from the Rheumatology clinic.
RA patient, not quite controlled, needs to optimized MTX therapy
Features Dr. Jack Cush https://t.co/ZoX2biwv7M
FDA sent an "untitled"letter to "R3 Stem Cell" for touting birth tissue products as Rx for ailments (without scientific evidence). FDA also won a case against "US Stem Cell clinics" for adulterated & misbranded stem cell products https://t.co/bQpRHxR9G8 https://t.co/oLBPKZ1lxX
Transparency is coming? The Prices will soon be Included in TV Drug Ads. HHS Secretary Alex Azar has finalized regulations requiring drug companies to disclose list prices of medications costing more than $35 for a month’s supply. https://t.co/P2DPwXGYXK



